Why have we failed to achieve neuroprotection in Parkinson's disease?
about
Missing pieces in the Parkinson's disease puzzleInhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's diseaseTurning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's DiseaseStem cells in human neurodegenerative disorders--time for clinical translation?Exenatide and the treatment of patients with Parkinson's diseaseTiming of deep brain stimulation in Parkinson disease: a need for reappraisal?Use of a self-rating scale of the nature and severity of symptoms in Parkinson's Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity.Behavioral phenotyping of mouse models of Parkinson's disease.Clinical progression in Parkinson disease and the neurobiology of axons.Unbiased approaches to biomarker discovery in neurodegenerative diseasesAlternative mitochondrial electron transfer as a novel strategy for neuroprotection.Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's diseaseJNK isoforms differentially regulate neurite growth and regeneration in dopaminergic neurons in vitro.Sigma-1 receptor: a potential new target for Parkinson's disease?Molecular chaperones in Parkinson's disease--present and futureCan the disease course in Parkinson's disease be slowed?Axon degeneration in Parkinson's diseaseThe effect of pramipexole therapy on balance disorder and fall risk in Parkinson's disease at early stage: clinical and posturographic assessmentPlasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's diseaseDistinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.Newly Diagnosed Anemia Increases Risk of Parkinson's disease: A Population-Based Cohort StudyComparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life StudyApoptosis signal-regulating kinase 1 (ASK1) is linked to neural stem cell differentiation after ischemic brain injury.Recognition and management of Parkinson's disease during the premotor (prodromal) phase.Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.Molecular and clinical prodrome of Parkinson disease: implications for treatment.Aetiopathogenesis of Parkinson's disease.Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.The bad, the good, and the ugly about oxidative stress.New synaptic and molecular targets for neuroprotection in Parkinson's disease.Cerebrospinal fluid biomarker candidates for parkinsonian disorders.Convection-Enhanced Delivery.Retrograde Axonal Degeneration in Parkinson Disease.RA Differentiation Enhances Dopaminergic Features, Changes Redox Parameters, and Increases Dopamine Transporter Dependency in 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells.Pramipexole reduces phosphorylation of α-synuclein at serine-129.Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.Idiopathic REM sleep behavior disorder and Parkinson's disease--two sides of one coin?
P2860
Q22251063-64E29997-C1A3-4571-A0F2-36D3157060B6Q24609725-A9214492-4FC9-4C16-9FDB-35DF80319CA3Q26770462-2D61C578-63AF-48CD-869D-CC8F4FE17BDBQ27687068-8FA59C52-7441-4E61-820F-5B728DAA3A79Q30540208-6F4F1E3F-FB5A-40F9-8DD5-DA31510F1007Q33785397-0BF490DF-7251-4EDF-8AF0-82267CC8FFA4Q33807815-5D149034-44EA-4D91-98CA-04FBC3A340CDQ33820609-9CE40855-1DC4-472C-989C-82D630AC9252Q34052764-0BE7D94E-CA79-4485-9556-18C0EF4123A8Q34625918-71B20968-1D64-4482-BE75-E1BC09B1D518Q34963810-81EC6132-68AD-4F3C-8063-075C397FCA76Q35106629-EBDDBDB7-D558-4BD6-8661-851BABF39726Q35228456-99B52DBC-70F4-482A-AD64-BC4FBE0005A8Q35537759-581ACB34-6F40-47FC-818E-41A45A2DA3A6Q35688796-9FB15205-F72D-438B-832B-C831B96F55EDQ35865171-28670A92-1CD2-4EB0-96F2-CC74733A79E2Q35923102-BF89F888-B914-4D07-A674-B0F017A1A67AQ36167437-54ACDD1F-BE5B-424B-BB42-85077DC594E4Q36172389-323590C0-6D52-4F7C-AC43-60EEE520D93AQ36275707-2C1005C7-9FD2-474B-A87B-AFF743E4CE2BQ36985371-35581C14-8DF0-421A-94FE-8B500CC30C3FQ37022421-AE9BF1E3-0E1B-4329-B279-C54E21C46559Q37093196-536431C1-EF38-4846-AA2B-3456F2C2DA81Q37265848-70B4EE05-6F26-43BD-9DB1-A00917116E3AQ37432078-ECED8CD8-08C0-48FB-8867-18A2B4F6FFAEQ37507968-82641865-3C47-475C-B79A-2AC715BCCC00Q37737032-9A06D179-49F5-4BD0-A098-FA4E6C707DEAQ37755975-5008A70B-04E9-476F-B027-819DD5C850DCQ37874190-BBC21F24-EFA4-4500-97D4-62CAAFCE6F12Q37963572-58DFC1CE-1A1E-49DC-8EDA-92BB5B136E3AQ38012450-DECB3BEB-1839-4128-AB48-B48C12C10801Q38038559-E4177425-6570-41D8-ACF2-9EEC4F7ECA66Q38076411-5ACD22C3-159F-4757-AB66-A239E950877BQ38744447-214D280D-6155-4DB4-9D82-212766BDAA26Q38785075-60F3CB5B-3A06-4B4C-9DD8-59771E621281Q38982597-F76358B5-FBBD-40CE-8A53-F50DF54A19B4Q39150857-A05E3C91-7922-4AAB-9C62-7F46ADF69391Q39443289-C8751833-0A18-450F-8DE6-E17796666A0FQ39681299-31E79B5F-70CA-403F-8573-08909568C49EQ40914241-8BD9CE1C-532C-41EF-83BC-082C4C724BB1
P2860
Why have we failed to achieve neuroprotection in Parkinson's disease?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Why have we failed to achieve neuroprotection in Parkinson's disease?
@en
Why have we failed to achieve neuroprotection in Parkinson's disease?
@nl
type
label
Why have we failed to achieve neuroprotection in Parkinson's disease?
@en
Why have we failed to achieve neuroprotection in Parkinson's disease?
@nl
prefLabel
Why have we failed to achieve neuroprotection in Parkinson's disease?
@en
Why have we failed to achieve neuroprotection in Parkinson's disease?
@nl
P50
P356
P1433
P1476
Why have we failed to achieve neuroprotection in Parkinson's disease?
@en
P2860
P304
P356
10.1002/ANA.21461
P478
64 Suppl 2
P577
2008-12-01T00:00:00Z